AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.